PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.
- Published In:
- Frontiers in pharmacology, 14, 1088670 (2023)
- Authors:
- Liu, Xu, Song, Ling, Zhang, Yuanhui, Li, Haiyan, Cui, Cheng, Liu, Dongyang
- Database ID:
- RPEP-07128
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07128APA
Liu, Xu; Song, Ling; Zhang, Yuanhui; Li, Haiyan; Cui, Cheng; Liu, Dongyang. (2023). PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.. Frontiers in pharmacology, 14, 1088670. https://doi.org/10.3389/fphar.2023.1088670
MLA
Liu, Xu, et al. "PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.." Frontiers in pharmacology, 2023. https://doi.org/10.3389/fphar.2023.1088670
RethinkPeptides
RethinkPeptides Research Database. "PEGylated exenatide injection (PB-119) improves beta-cell fu..." RPEP-07128. Retrieved from https://rethinkpeptides.com/research/liu-2023-pegylated-exenatide-injection-pb119
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.